Malcolm J Moore

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Brief communication: a new combination in the treatment of advanced pancreatic cancer
    Malcolm J Moore
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Semin Oncol 32:5-6. 2005
  2. ncbi request reprint Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    M J Moore
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 21:3296-302. 2003
  3. ncbi request reprint Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
  4. ncbi request reprint Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
    C A Townsley
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 21:1524-9. 2003
  5. ncbi request reprint Pancreatic cancer: what the oncologist can offer for palliation
    Malcolm J Moore
    Department of Medicine, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Can J Gastroenterol 16:121-4. 2002
  6. doi request reprint Sorafenib for metastatic renal cancer: the Princess Margaret experience
    Rachel P Riechelmann
    Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Am J Clin Oncol 31:182-7. 2008
  7. ncbi request reprint Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial
    Jennifer J Knox
    Princess Margaret Hospital, 5 218, 610 University Ave, Toronto, Ontario, Canada
    J Clin Oncol 23:2332-8. 2005
  8. doi request reprint A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5 222, Toronto, Ontario M5G 2M9, Canada
    Invest New Drugs 29:1045-9. 2011
  9. doi request reprint A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer
    Srikala S Sridhar
    Princess Margaret Hospital, Toronto, ON, Canada
    Am J Clin Oncol 33:609-13. 2010
  10. doi request reprint A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J Renouf
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Cancer Chemother Pharmacol 69:1339-44. 2012

Detail Information

Publications77

  1. ncbi request reprint Brief communication: a new combination in the treatment of advanced pancreatic cancer
    Malcolm J Moore
    Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Semin Oncol 32:5-6. 2005
    ..Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer...
  2. ncbi request reprint Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    M J Moore
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 21:3296-302. 2003
    ..To compare the selective matrix metalloproteinase inhibitor BAY 12-9566 with the nucleoside analog gemcitabine in the treatment of advanced pancreatic cancer...
  3. ncbi request reprint Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
    ..We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer...
  4. ncbi request reprint Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
    C A Townsley
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, M5G 2M9 Canada
    J Clin Oncol 21:1524-9. 2003
    ....
  5. ncbi request reprint Pancreatic cancer: what the oncologist can offer for palliation
    Malcolm J Moore
    Department of Medicine, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Can J Gastroenterol 16:121-4. 2002
    ..Among the most promising are farnesyl protein transferase inhibitors, which modulate K-ras function. Such an approach is promising for the treatment of pancreatic cancer because this tumour frequently exhibits mutation of the ras gene...
  6. doi request reprint Sorafenib for metastatic renal cancer: the Princess Margaret experience
    Rachel P Riechelmann
    Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Am J Clin Oncol 31:182-7. 2008
    ..Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program...
  7. ncbi request reprint Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial
    Jennifer J Knox
    Princess Margaret Hospital, 5 218, 610 University Ave, Toronto, Ontario, Canada
    J Clin Oncol 23:2332-8. 2005
    ..The objectives of this trial were to determine the response rate, time to disease progression, survival, and safety profile of the combination of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer...
  8. doi request reprint A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5 222, Toronto, Ontario M5G 2M9, Canada
    Invest New Drugs 29:1045-9. 2011
    ..Secondary endpoints included rate of prolonged stable disease (>3 months), time to progression, median and 1 yr survival and safety and tolerability...
  9. doi request reprint A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer
    Srikala S Sridhar
    Princess Margaret Hospital, Toronto, ON, Canada
    Am J Clin Oncol 33:609-13. 2010
    ..This Phase II multicenter clinical trial is the first to evaluate Lapatinib in early stage, hormonally untreated recurrent or metastatic prostate cancer...
  10. doi request reprint A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J Renouf
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Cancer Chemother Pharmacol 69:1339-44. 2012
    ..We conducted a single arm phase II study to evaluate the safety and efficacy of bevacizumab in combination with dose-reduced capecitabine and irinotecan in patients with previously untreated mCRC...
  11. doi request reprint A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
    Daniel J Renouf
    Division of Medical Oncology and Hematology, Rm 5 708, Princess Margaret Hospital, 610 University Avenue, Toronto M5G2M9, Canada
    Invest New Drugs 30:779-86. 2012
    ..The aims were to define the recommended phase II dose (RP2D) of saracatinib when combined with gemcitabine, and assess the efficacy of this combination in advanced pancreatic cancer...
  12. ncbi request reprint Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases
    Paula N Fishman
    Department of Hematology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Am J Clin Oncol 29:225-31. 2006
    ..A retrospective analysis was conducted of patients with advanced small bowel adenocarcinoma to explore chemotherapy use, and gain knowledge for ongoing management and future clinical trials...
  13. doi request reprint Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3
    Gilda da Cunha Santos
    Department of Pathology, University Health Network, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer 116:5599-607. 2010
    ..Mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and EGFR gene copy number (GCN) were evaluated as predictive markers in 26% of patients who had tumor samples available for analysis...
  14. doi request reprint A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
    Srikala S Sridhar
    Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5 222, Toronto, ON M5G 2M9, USA
    Cancer Chemother Pharmacol 67:927-33. 2011
    ..This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC)...
  15. doi request reprint A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
    Daniel J Renouf
    University Health Network Princess Margaret Hospital, Toronto, ON, Canada
    Invest New Drugs 30:1203-7. 2012
    ..This phase II study of eribulin in patients with advanced pancreatic cancer previously treated with gemcitabine was conducted by the Princess Margaret Hospital Phase II consortium...
  16. ncbi request reprint Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination
    Carol A Townsley
    Princess Margaret Hospital Phase II Consortium, Ontario, Canada
    Clin Cancer Res 12:2141-9. 2006
    ..Adverse event data from clinical trials in the Princess Margaret Hospital Phase II Consortium database were analyzed to address this question...
  17. doi request reprint A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Srikala S Sridhar
    Princess Margaret Hospital, Toronto, ON, Canada
    Invest New Drugs 31:1008-15. 2013
    ..In this single arm phase 2 study, we evaluated the efficacy and tolerability of cediranib (AZD2171) a potent angiogenesis inhibitor in first line mRCC...
  18. doi request reprint Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
    Lillian L Siu
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 31:2477-84. 2013
    ..The addition of brivanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has shown encouraging early clinical activity...
  19. ncbi request reprint Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
    Lillian L Siu
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9
    Clin Cancer Res 12:144-51. 2006
    ..This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities...
  20. doi request reprint Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
    Nicole Mittmann
    Health Outcomes and Pharmacoeconomics Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    J Natl Cancer Inst 101:1182-92. 2009
    ..17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274)...
  21. doi request reprint Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience
    Jeremy F Sturgeon
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Eur Urol 59:556-62. 2011
    ..Since 1981 Princess Margaret Hospital has used initial active surveillance (AS) with delayed treatment at relapse as the preferred management for all patients with clinical stage I nonseminomatous germ cell tumors (NSGCT)...
  22. doi request reprint Quality of life in patients with K-RAS wild-type colorectal cancer: The CO.20 Phase 3 Randomized Trial
    Jolie Ringash
    Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Cancer 120:181-9. 2014
    ..The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo)...
  23. ncbi request reprint Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours
    Lyly H Le
    Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    Cancer Chemother Pharmacol 56:154-60. 2005
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) of zosuquidar in combination with vinorelbine. The effects of zosuquidar on vinorelbine pharmacokinetics were also examined...
  24. doi request reprint Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital
    Jeff Rothenstein
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Am J Clin Oncol 31:64-70. 2008
    ..Over the past decade, novel treatment approaches have been developed. The purpose of this study was to review the experience at the Princess Margaret Hospital in treating patients with NET over the past decade...
  25. doi request reprint Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
    Natasha B Leighl
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:2077-84. 2011
    ..We examined its impact on patient understanding, treatment decisions, decisional conflict, decision making, consultation satisfaction, anxiety, and quality of life by using a randomized trial design...
  26. ncbi request reprint A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer
    Eric Winquist
    London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:143-9. 2005
    ....
  27. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
    ..This study determined the recommended phase II dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced non-small cell lung cancer (NSCLC)...
  28. doi request reprint Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer
    Christopher Lo
    Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 28:3084-9. 2010
    ..We therefore conducted a longitudinal study to determine the course and predictors of depressive symptoms...
  29. doi request reprint Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer
    Patricia A Tang
    Princess Margaret Phase II Consortium, Toronto, Ontario, Canada
    Clin Cancer Res 18:6023-31. 2012
    ..We assessed the safety and efficacy of aflibercept in patients with metastatic colorectal cancer (MCRC) who had received at least one prior palliative regimen...
  30. doi request reprint Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials
    Christophe Le Tourneau
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    J Clin Oncol 28:1401-7. 2010
    ..There is no consensus on which preclinical models and parameters should define the starting dose for molecularly targeted agents...
  31. ncbi request reprint Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial
    Michelle Nottage
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    Support Care Cancer 11:41-7. 2003
    ..Patient reporting of mucositis is a more sensitive instrument for assessment of mucositis than review by medical staff...
  32. ncbi request reprint Epidermal growth factor receptor expression in anal canal carcinoma
    Lyly H Le
    Department of Medical Oncology, Fraser Valley Cancer Centre, Surrey, Canada
    Am J Clin Pathol 124:20-3. 2005
    ..The 21 samples studied universally and strongly expressed EGFR and were negative for HER-2. Clinical studies of EGFR inhibitors in advanced ACC are warranted...
  33. ncbi request reprint Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer
    Stephen A Welch
    Princess Margaret Hospital, 5 700, 610 University Avenue Toronto, Ontario M5G 2M9, Canada
    Future Oncol 3:247-54. 2007
    ..Erlotinib-induced rash appears to be predictive of outcome. Further clinical studies of erlotinib in the treatment of pancreatic cancer are ongoing...
  34. ncbi request reprint Targeting metastatic prostate cancer: the search for innovative systemic therapies
    Dominik R Berthold
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto Toronto, Ontario, Canada
    Oncology (Williston Park) 20:1787-91; discussion 1791-6. 2006
    ..However, none of the new treatment modalities has yet been shown to be more effective than standard treatments. This article will provide an overview of targeted or innovative therapies in the treatment of prostate cancer...
  35. ncbi request reprint A Phase II study of oxaliplatin in urothelial cancer
    Eric Winquist
    Princess Margaret Hospital Phase II Consortium, London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:150-4. 2005
    ..To assess the antitumor activity of oxaliplatin, a third generation platinum derivative with a 1,2-diaminocyclohexane (DACH) carrier ligand, in patients with metastatic transitional cell carcinoma of the bladder (TCC)...
  36. ncbi request reprint Phase II study of activated charcoal to prevent irinotecan-induced diarrhea
    Michael Michael
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 22:4410-7. 2004
    ..The aim of this study was to assess whether activated charcoal (AC), possibly by adsorbing free lumenal SN38, can reduce irinotecan-induced diarrhea (CID) and optimize its dose-intensity...
  37. ncbi request reprint Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
    A Patnaik
    Princess Margaret Hospital, Ontario Cancer Institute, Toronto, Canada
    J Clin Oncol 18:3677-89. 2000
    ....
  38. ncbi request reprint Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity
    D R Rauchwerger
    Department of Pharmacology, University of Toronto, Ontario, Canada
    Cancer Res 60:6075-9. 2000
    ..This was also associated with a significant increase in es-NT levels caused by the TS inhibitors. Thus, modulation of the es-NT by pretreatment with TS inhibitors may have the potential to improve the therapeutic benefit of gemcitabine...
  39. pmc Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
    X Chen
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Canada M5G 2M9
    Br J Cancer 89:617-24. 2003
    ..This combination regimen has promising broad antitumour activity, and will be further evaluated in phase II studies in multiple tumour types...
  40. ncbi request reprint Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience
    J J Knox
    Departments of Hematology and Medical Oncology, Princess Margaret Hospital University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Ann Oncol 15:770-4. 2004
    ..Unresectable biliary tract cancer has a very poor prognosis. A combination of weekly gemcitabine plus continuous infusional 5-fluorouracil (5-FU) (GEM/CVI 5-FU) was evaluated as therapy for this cancer...
  41. doi request reprint Alternate endpoints for screening phase II studies
    Neesha Dhani
    Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 15:1873-82. 2009
    ..Alternate endpoints, although promising, require additional evaluation and prospective validation before their use as a primary endpoint for phase II trials...
  42. doi request reprint Advanced pancreatic carcinoma: current treatment and future challenges
    Anastasios Stathis
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, ON M5G 2M9, Canada
    Nat Rev Clin Oncol 7:163-72. 2010
    ..We review the current standards of care for patients with locally advanced and metastatic pancreatic carcinoma and outline some future directions for the development of new treatment strategies...
  43. doi request reprint Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer
    David W Cescon
    Department of Medicine, University of Toronto, Toronto, Canada
    J Clin Oncol 26:2214-5. 2008
  44. doi request reprint A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer
    Srikala S Sridhar
    Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada
    Oncologist 13:95-7. 2008
    ..Furthermore, these patients can now be treated with a new class of antiangiogenic agents that are showing impressive response rates, which may also translate into improved overall survival...
  45. ncbi request reprint Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum
    James D Brierley
    Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital Ontario Cancer Institute, University Health Network, Toronto Ontario, Canada
    Acta Oncol 43:567-70. 2004
    ..In view of the changes in surgical and pathological techniques in the last decade, further studies are required to determine the merits or otherwise of postoperative Short Course Adjuvant Radiation...
  46. ncbi request reprint Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group
    C M Canil
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 23:455-60. 2005
    ....
  47. ncbi request reprint Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
    Wenjiang Zhang
    Department of Experimental Therapeutics, Ontario Cancer Institute, Ontario, Canada
    J Chromatogr B Analyt Technol Biomed Life Sci 814:143-7. 2005
    ..Values of between- and within-day precision and accuracy for both OSI-774 and OSI-420 were <20%. This method was successfully applied to study steady-state pharmacokinetics of OSI-774 and OSI-420 in a phase II clinical trial...
  48. ncbi request reprint A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
    ..Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad spectrum cellular effects...
  49. ncbi request reprint A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix
    Jennifer J Knox
    Departments of Medical Oncology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, 5 218, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Eur J Cancer 41:523-30. 2005
    ..We conclude that the administration of lovastatin at 7.5 mg/kg/day for 21 consecutive days on a 28-day schedule is well tolerated in patients with good renal function and warrants further clinical evaluation...
  50. ncbi request reprint A review of erlotinib and its clinical use
    Patricia A Tang
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, M5G 2M9, Canada
    Expert Opin Pharmacother 7:177-93. 2006
    ..Predictive factors for response include the presence of a rash, epidermal growth factor receptor expression and mutation status. This article reviews the current clinical status of erlotinib...
  51. ncbi request reprint Novel targets in prostate cancer
    Dominik R Berthold
    Princess Margaret Hospital and University of Toronto, Department of Medical Oncology and Hematology, 610 University Avenue Toronto, Ontario M5G 2M9, Canada
    Expert Opin Ther Targets 10:777-80. 2006
    ....
  52. ncbi request reprint Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  53. ncbi request reprint Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer
    M J Moore
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 15:3441-5. 1997
    ..To evaluate the efficacy and toxicity of gemcitabine (2',2'-difluorodeoxycytidine) in previously untreated patients with advanced transitional cell carcinoma...
  54. pmc Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    C A Townsley
    Princess Margaret Hospital Phase II Consortium, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Br J Cancer 94:1136-43. 2006
    ..More than one-third of evaluable patients had s.d. for a minimum of 8 weeks. Correlative studies showed a reduction in phosphorylated EGFR and ERK in tumour tissue post-treatment...
  55. ncbi request reprint Treatment of hormone refractory prostate cancer
    J J Knox
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Canada
    Semin Urol Oncol 19:202-11. 2001
    ..Given the relative insensitivity of prostate cancer to cytotoxic agents, this area holds much potential...
  56. ncbi request reprint A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer
    A J Dowling
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
    Ann Oncol 12:773-8. 2001
    ..PSA response was associated with longer survival. Patients treated with M + P were more likely to achieve a PSA response and a palliative response than those treated with P...
  57. ncbi request reprint Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days
    Lyly H Le
    Princess Margaret Hospital, Toronto, ON, Canada
    Invest New Drugs 22:159-67. 2004
    ..New methods for synthesizing fostriecin have recently been described and therefore further development of this unique anticancer agent may be warranted...
  58. ncbi request reprint Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres
    D Scott Ernst
    London Regional Cancer Centre, London, Ontario, Canada
    Can J Urol 12:2575-80. 2005
    ..We evaluate the impact of surveillance programs on the outcome of men with clinical stage 1 NSGCT following orchidectomy...
  59. ncbi request reprint The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
    Helen G Juffs
    Princess Margaret Hospital, Ontario, Toronto, Canada
    Lancet Oncol 3:738-47. 2002
    ..Other trials should address the role of molecular markers in selecting patients for chemotherapy. Whenever possible, chemotherapy for locally advanced muscle-invasive TCC should be given in the context of a well-designed clinical trial...
  60. ncbi request reprint Pharmacological determinants of 9-aminocamptothecin cytotoxicity
    M L Li
    Faculty of Pharmacy University of Toronto, Ontario, Canada
    Clin Cancer Res 7:168-74. 2001
    ..85, which indicated that duration of exposure was more important than concentration. Our data support the use of 9-AC by infusion for 24 h or longer in clinical studies providing target plasma concentrations can be achieved...
  61. doi request reprint The treatment of advanced pancreatic cancer: current evidence and future challenges
    M J Moore
    Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 19:vii304-8. 2008
  62. ncbi request reprint Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications
    J Dimitroulakos
    Division of Cellular and Molecular Biology Ontario Cancer Institute, University Health Network, Toronto, Canada
    Clin Cancer Res 7:158-67. 2001
    ..Thus, we have identified a subset of tumors that are sensitive to lovastatin-induced apoptosis and show HMG-CoA reductase as a potential therapeutic target of these cancers...
  63. ncbi request reprint Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract
    E Winquist
    Division of Medical Oncology, Ontario N6A 4L6, London, Canada
    Eur J Cancer 39:1866-71. 2003
    ..The activity and unique toxicity profile of this drug make it of interest for further study in advanced urothelial cancers in combination with other active agents...
  64. pmc Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function
    T Muzzammil
    Department of Pharmaceutical Sciences, University of Toronto, 610 University Avenue, Toronto, Ontario, M5G 2M9, Canada
    Br J Cancer 84:367-73. 2001
    ..Thus, both methods clearly distinguished sensitive from resistant MCF7 variants, with the radionuclide method showing greater sensitivity...
  65. pmc Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?
    M J Moore
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    Br J Cancer 62:988-91. 1990
    ..We conclude that treatment strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method of using surrogate questionnaires is a valuable aid to the design of clinical trials...
  66. ncbi request reprint Counterpoint: Men should be treated for hormone refractory prostate cancer with systemic chemotherapy when they are symptomatic, and not before
    Malcolm J Moore
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 10:2038-9. 2003
    ..It will also limit or eliminate any therapeutic options when symptoms eventually develop and therapy is needed most...
  67. ncbi request reprint Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
    Stephen A Welch
    J Clin Oncol 25:2159-61. 2007
  68. ncbi request reprint Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Herne, Germany
    Oncologist 12:426-37. 2007
    ..Based on these findings, continuous daily 400 mg bid sorafenib was chosen as the optimal regimen for phase II/III studies. Trials are ongoing in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer...
  69. ncbi request reprint A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gonzalo Gomez-Abuin
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Invest New Drugs 25:181-5. 2007
    ....
  70. doi request reprint Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials
    Emmanuel Mitry
    Hépato gastroentérologie et oncologie digestive, Hopital Ambroise Pare, Boulogne, France
    J Clin Oncol 26:4906-11. 2008
    ..We report here a pooled analysis based on individual data from these two trials...
  71. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  72. ncbi request reprint Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer
    Howard S Hochster
    Department of Medicine Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:676-85. 2006
    ..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented...
  73. ncbi request reprint Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks
    Alison J Davis
    National Cancer Institute, Canada
    Invest New Drugs 21:85-97. 2003
    ..This phase I study examined the toxicity and pharmacologic profile of MG98 administered as a continuous 21-day intravenous infusion every 4 weeks...
  74. pmc Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
    Christine M Ribic
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto
    N Engl J Med 349:247-57. 2003
    ..We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer...
  75. ncbi request reprint Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue
    Carlton K K Lee
    Department of Oncology, Johns Hopkins University and Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA
    Clin Cancer Res 12:2158-65. 2006
    ....
  76. ncbi request reprint Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    ..To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC)...
  77. ncbi request reprint Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007
    ..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...